Isabelle Bernard-Pierrot

List of Publications by Year
in descending order

17 papers	1,761 citations	687363 13 h-index	888059 17 g-index
21 all docs	21 docs citations	21 times ranked	2463 citing authors

#	Article	IF	Citations
1	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	1.9	741
2	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Science Translational Medicine, 2014, 6, 244ra91.	12.4	304
3	Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. Cell Reports, 2014, 9, 1235-1245.	6.4	181
4	Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis, 2006, 27, 740-747.	2.8	128
5	Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. European Journal of Cancer, 2021, 148, 181-189.	2.8	70
6	An <scp>FGFR</scp> 3/ <scp>MYC</scp> positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Molecular Medicine, 2018, 10, .	6.9	54
7	An essential role for decorin in bladder cancer invasiveness. EMBO Molecular Medicine, 2013, 5, 1835-1851.	6.9	45
8	A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. Nature Communications, 2021, 12, 5578.	12.8	45
9	Recurrent activating mutations of PPARÎ³ associated with luminal bladder tumors. Nature Communications, 2019, 10, 253.	12.8	44
10	Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. Genome Medicine, 2020, 12, 85.	8.2	39
11	APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. European Urology, 2019, 76, 9-13.	1.9	34
12	Interleukin-7 receptor Î± mutational activation can initiate precursor B-cell acute lymphoblastic leukemia. Nature Communications, 2021, 12, 7268.	12.8	24
13	TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer. British Journal of Cancer, 2019, 120, 555-564.	6.4	23
14	Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 5510-5530.	3.0	11
15	Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives. Cancers, 2021, 13, 87.	3.7	10
16	Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsendâ€™s Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9â€“13. European Urology, 2020, 77, e26-e27.	1.9	3
17	Triple extraction method enables high quality mass spectrometryâ€based proteomics and phosphoâ€proteomics for eventual multiâ€omics integration studies. Proteomics, 2021, 21, 2000303.	2.2	2